QUANTUM GENOMICS : Quantum Genomics announces the appointment of Dr Olivier Madonna as Chief Medical Officer

information fournie par Actusnews•27/11/2014 à 19:20

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, strengthens its organization and management team with the appointment of Dr Olivier Madonna as Chief Medical Officer of the company.

Olivier Madonna will be in charge of the clinical developments of Quantum Genomics' drug candidates and of the relations with regulatory authorities and drug safety agencies.

He will also lead the work on patients' stratification and products positioning.

Olivier Madonna has a broad international experience as head of medical departments of pharmaceutical and biotechnology companies.

At Merck & Co, he acquired an in depth knowledge of the clinical development of antihypertensive drugs, such as Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin II Receptor Blockers (ARBs).

He also was head of European Medical Affairs at Johnson & Johnson, in charge of several worldwide cardiovascular clinical trials and European registrations.

As European Medical Director, he set up and managed several clinical trials in the hypertension and heart failure areas for the American-Australian group Resmed and for the Indian group Wockhardt.

Olivier Madonna graduated as Medical Doctor from the University Claude Bernard in Lyon. He is a member of the French societies of Cardiology, Pharmacology, Nephrology and Hypertension. Former Intern then clinical head at Lyon Hospitals, he became attending physician in Nephrology at the Public Assistance - Paris Hospitals (APHP).

Commenting on this appointment, Lionel Segard, Chairman and CEO of Quantum Genomics says:

“ We are pleased to have Olivier Madonna on board. He will strengthen our team and bring his experience at achieving Phase II and III clinical trials. He will manage, in collaboration with Pr Michel AZIZI, Director of the clinical investigation Center at the European Hospital Georges Pompidou, the Phase II clinical trial of QGC001 which has just been approved by the regulatory authorities in France.

Moreover, as he maintained in recent years his specialized medical activities in the very same field of research as Quantum Genomics, he will stay connected to patients' expectations, especially in terms of unmet medical needs”.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).

Contacts